BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Genfit

Genfit logo

Founded
1999
Patents
72
Clinical Trials
19
Publications
20

Technologies

AI Companies (Drug Discovery)

Genfit SA, a biopharmaceutical company, engages in the research and development of drugs for the prevention and treatment of cardiometabolic and neurodegenerative diseases. The company focuses on various therapeutic areas, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer's diseases. Its lead proprietary program, GFT505, is an oral drug candidate under Phase II clinical trial for the treatment of pre-diabetes/diabetes. The company's products also include AVE0897 and SLV341, which are in Phase I clinical trial for the treatment of diabetes; SLV342, a pre-clinical product for the treatment of atherosclerosis; SAVX1, a pre-clinical products for the treatment of diabetes and vascular inflammation; BMGFT02, a pre-clinical product for the treatment of pre-diabetes/diabetes and beta-cell failure; and BMGFT01, a pre-clinical stage product for the treatment of Atherosclerosis. It has various collaboration, partnership, and strategic agreements with Sanofi-Aventis, Solvay group, Servier, and Merck.

Become a Member to view additional information about this company